BHC Stock Analysis: Bausch Health Companies | NYSE
Drug Manufacturers - Specialty & Generic | NYSE, USA | Market Cap: 2.169m USD | 12M Return: -11.5% | CA0717341071 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 10.7M
EPS Trend: 84.9%
Qual. Beats: 1
Rev. Trend: 99.4%
Qual. Beats: 4
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Bausch Health Companies Inc. (NYSE: BHC) is a Canadian-headquartered, mid-cap specialty pharmaceutical and medical device company that develops, manufactures, and markets products across five reporting segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. Its portfolio spans gastroenterology, hepatology, neurology, dermatology, generic and branded generic pharmaceuticals, dentistry, over-the-counter consumer health products, aesthetic medical devices, and eye health. The company distributes its products across more than a dozen countries, including the United States, China, Canada, and several European and Asia-Pacific markets.
Previously known as Valeant Pharmaceuticals International, Inc., the company rebranded as Bausch Health in July 2018. Bausch + Lomb, its eye health segment, is one of the most globally recognized brands in ophthalmology, with roots dating back to the 19th century, and is frequently cited as a potential spin-off candidate. As a diversified specialty pharma player, Bausch Health generates revenue from a mix of branded prescription drugs, generics, consumer health products, and medical devices, which differentiates it from larger pure-play pharmaceutical peers.
- Bausch + Lomb IPO spinoff unlocks standalone valuation
- Salix gastroenterology franchise faces generic Xifaxan competition
- Debt reduction from asset sales drives deleveraging plan
- International segment growth depends on China and Canada pricing
| Net Income: -1.10b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA 1.57 > 1.0 |
| NWC/Revenue: 18.23% < 20% (prev 15.61%; Δ 2.61% < -1%) |
| CFO/TA 0.07 > 3% & CFO 1.80b > Net Income -1.10b |
| Net Debt (19.0b) to EBITDA (2.05b): 9.28 < 3 |
| Current Ratio: 1.44 > 1.5 & < 3 |
| Outstanding Shares: last quarter (378.1m) vs 12m ago 1.34% < -2% |
| Gross Margin: 71.82% > 18% (prev 70.70%; Δ 1.12% > 0.5%) |
| Asset Turnover: 41.69% > 50% (prev 36.15%; Δ 5.54% > 0%) |
| Interest Coverage Ratio: 0.54 > 6 (EBIT TTM 875.0m / Interest Expense TTM 1.61b) |
| A: 0.08 (Total Current Assets 6.52b - Total Current Liabilities 4.54b) / Total Assets 24.8b |
| B: -0.44 (Retained Earnings -10.8b / Total Assets 24.8b) |
| C: 0.03 (EBIT TTM 875.0m / Avg Total Assets 26.0b) |
| D: -0.07 (Book Value of Equity -1.77b / Total Liabilities 25.6b) |
| Altman-Z'' = -0.75 = B |
| DSRI: 0.93 (Receivables 2.26b/2.21b, Revenue 10.9b/9.86b) |
| GMI: 0.98 (GM 70.70% / 71.82%) |
| AQI: 0.95 (AQ_t 0.65 / AQ_t-1 0.69) |
| SGI: 1.10 (Revenue 10.9b / 9.86b) |
| TATA: -0.12 (NI -1.10b - CFO 1.80b) / TA 24.8b) |
| Beneish M = -3.07 (Cap -4..+1) = AA |
As of October 04, 2026, the stock is trading at USD 5.80 with a total of 3,235,809 shares traded. Over the past week, the price has changed by +1.93%, over one month by -15.08%, over three months by +18.37% and over the past year by -11.45%.
Current recommended Stop Loss: 5.30 (which is 8.6% or 2.1 ATR below the current price).
Bausch Health Companies has received a consensus analysts rating of 3.00. Therefore, it is recommended to hold BHC.
- StrongBuy: 0
- Buy: 1
- Hold: 5
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 7.5 | 29.3% |
P/E Forward = 1.3101
P/S = 0.1999
P/B = 18.7773
P/EG = 0.011
Revenue TTM = 10.9b USD
EBIT TTM = 875.0m USD
EBITDA TTM = 2.05b USD
Long Term Debt = 19.9b USD (from longTermDebt, last quarter)
Short Term Debt = 881.0m USD (from shortTermDebt, last quarter)
Debt = 20.8b USD (from shortLongTermDebtTotal, last quarter) + Leases 38.0m
Net Debt = 19.0b USD (calculated: Debt 20.8b - CCE 1.82b)
Enterprise Value = 21.2b USD (2.17b + Debt 20.8b - CCE 1.82b)
Interest Coverage Ratio = 0.54 (Ebit TTM 875.0m / Interest Expense TTM 1.61b)
EV/FCF = 15.20x (Enterprise Value 21.2b / FCF TTM 1.39b)
FCF Yield = 6.58% (FCF TTM 1.39b / Enterprise Value 21.2b)
FCF Margin = 12.83% (FCF TTM 1.39b / Revenue TTM 10.9b)
Net Margin = -10.12% (Net Income TTM -1.10b / Revenue TTM 10.9b)
Gross Margin = 71.82% ((Revenue TTM 10.9b - Cost of Revenue TTM 3.06b) / Revenue TTM)
Gross Margin QoQ = 72.93% (prev 70.76%)
Tobins Q-Ratio = 0.85 (Enterprise Value 21.2b / Total Assets 24.8b)
Interest Expense / Debt = 7.72% (Interest Expense 1.61b / Debt 20.8b)
Taxrate = 25.29% (88.0m / 348.0m)
NOPAT = 653.7m (EBIT 875.0m * (1 - 25.29%))
Current Ratio = 1.44 (Total Current Assets 6.52b / Total Current Liabilities 4.54b)
Debt / Equity = -11.75 (negative equity) (Debt 20.8b / totalStockholderEquity, last quarter -1.77b)
Debt / EBITDA = 9.28 (Net Debt 19.0b / EBITDA 2.05b)
Debt / FCF = 13.64 (Net Debt 19.0b / FCF TTM 1.39b)
Total Stockholder Equity = -1.24b (last 4 quarters mean from totalStockholderEquity)
RoA = -4.22% (Net Income -1.10b / Total Assets 24.8b)
RoE = 88.77% (negative equity) (Net Income TTM -1.10b / Total Stockholder Equity -1.24b)
RoCE = 4.69% (EBIT 875.0m / Capital Employed (Equity -1.24b + L.T.Debt 19.9b))
RoIC = 3.18% (NOPAT 653.7m / Invested Capital 20.6b)
WACC = 6.22% (E(2.17b)/V(23.0b) * Re(10.58%) + D(20.8b)/V(23.0b) * Rd(7.72%) * (1-Tc(0.25)))
Discount Rate = 10.58% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 78.95 | Cagr: 1.36%
[DCF] Terminal Value 77.97% ; FCFF base≈1.28b ; Y1≈1.46b ; Y5≈2.15b
[DCF] Fair Price = 35.90 (EV 32.4b - Net Debt 19.0b = Equity 13.4b / Shares 374.0m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 84.86 | EPS CAGR: 5.69% | SUE: 2.32 | # QB: 1
Revenue Correlation: 99.43 | Revenue CAGR: 8.45% | SUE: 4.0 | # QB: 4
EPS current Quarter (2026-09-30): EPS=1.19 | Chg30d=-6.95% | Revisions=-17% | Analysts=5
EPS current Year (2026-12-31): EPS=4.47 | Chg30d=+1.02% | Revisions=+17% | GrowthEPS=+19.2% | GrowthRev=+6.0%
EPS next Year (2027-12-31): EPS=4.19 | Chg30d=-0.58% | Revisions=-17% | GrowthEPS=-6.1% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: -8% (up=4, down=5)